State Supported Living Centers Statewide Policy & Procedures. Psychiatry Services POLICY:
|
|
- Amberlynn Greene
- 7 years ago
- Views:
Transcription
1 State Supported Living Centers Statewide Policy & Procedures Policy Number: Effective: MM/DD/YYYY DRAFT Replaces: POLICY: PURPOSE: Psychiatry Services The purpose of this policy is to ensure that the individuals served receive psychiatric care consistent with generally accepted practice standards at State Supported Living Centers (SSLCs) and the ICF component of the Rio Grande State Center ( state centers ). APPROVED BY: Joe Vesowate Assistant Commissioner State Supported Living Centers APPLIES TO: State center employees, volunteers, contractors, and subcontractors. The provisions of this policy may not apply to prescribing practice in research projects that have been approved in accordance with DADS policies and procedures concerning the review and approval of research involving human subjects. DISTRIBUTION: The state center must ensure the policy, all exhibits, and forms are distributed to applicable staff, contractors, agents, and any individual requesting a copy. CONTACT: Eric Moorad Policy/Rules Coordinator (512) EXHIBIT AND FORM: Exhibit: Exhibit A Psychotropic Medication List Exhibit B Appendix B of the SA, with information added REFERENCES: Settlement Agreement (SA), Section J and Health Care Guidelines 40 Texas Administrative Code, Chapter 5, Subchapter A and Chapter 8, Subchapter I Agency for Healthcare Research and Quality Guidelines: x Medication Audit Criteria and Guidelines: ms/medaudcriteria.shtm Page 1 of 10
2 I. State Center Responsibilities A. The state center must ensure that individuals receive needed integrated clinical services, including psychiatry. B. The state center must provide psychiatric services only by persons who are qualified professionals. C. The state center must ensure that psychiatric consultation is available and that sufficient numbers of staff or contract psychiatrists, board certified/eligible psychiatrists, psychiatric advanced practice registered nurses (APRNs), and/or psychiatric physician assistants are available to provide appropriate psychiatric care to all individuals who reside in the State Centers. D. The state center must ensure that individuals are evaluated and diagnosed by a psychiatrist prior to administration of psychotropic medications. The documentation of the psychiatric evaluation must follow the format in Exhibit A to this policy. E. The state center must develop and implement a system to integrate pharmacological treatments with behavioral and other interventions through disciplinary assessments and combined formulation. F. Psychotropic medication must not be used as punishment, for convenience of staff, as a substitute for appropriate psychosocial treatments, or in the absence of a psychiatric diagnosis, neuropsychiatric diagnosis, or specific behavioral-pharmacological hypothesis. G. The state center must promulgate procedures governing the scope of practice regarding prescription of psychotropic medications when the prescribing professional is not a psychiatrist. H. The state center must provide education about psychotropic medications when appropriate to individuals, their families, and/or their legally authorized representatives (LARs) according to accepted guidelines. 1. If accepted guidelines do not exist, the education must address characteristics of the medication, including expected benefits, potential adverse or side effects, dosage, standard alternative treatments, legal rights, and any questions the individual, the family, and/or LAR may have. 2. Education should also address significant changes in the individual's medication regimen. I. The state center must obtain informed consent (except in the case of an emergency) prior to administering psychotropic medications or other restrictive procedures. Page 2 of 10
3 J. Prescription of psychotropic medications must comply with all relevant ICF/IID conditions of participation. K. The prescribing professional must practice within the scope of the person s license with supervision as appropriate to that license. II. Pre-Treatment Sedation A. Appropriate staff (i.e., psychiatry, pharmacy, medical, nursing, and psychology) reviews Pre-Treatment Sedation (PTS) orders for both routine dental and/or medical treatment for all individuals on psychotropic medication. B. The IDT documents PTS, noting current treatments, strategies or programming, including desensitization plans, to minimize or eliminate the need for PTS. The IDT must confirm individuals who receive PTS have ongoing assessment and monitoring of effectiveness of strategies or programming to eliminate or reduce the reliance on PTS. C. The IDT must coordinate PTS with other medications, supports and services, and as appropriate psychiatric, pharmacy and medical services. D. Nursing staff assesses and monitors individuals pre- and post-treatment, including for side effects. III. Assessment and Diagnosis A. A psychiatrist may use evidence-based clinical practice guidelines promulgated by national and international organizations and from the federal and Texas governments to guide practice. In the absence of evidence-based clinical practice guidelines applicable to a specific situation, the psychiatrist uses clinical judgment and applies current generally accepted standards of practice. B. The state center must conduct an initial Reiss screen: 1. Within 30 days of admission for all newly admitted individuals who are not on any psychotropic medication for a psychiatric diagnosis; and 2. For individuals residing at the state center who do not have a current psychiatric assessment and thereafter, as clinically indicated and recommended by the IDT. C. The state center must complete a comprehensive psychiatric evaluation for: 1. Any individual identified as needing a comprehensive psychiatric evaluation based on a Reiss screen; and Page 3 of 10
4 2. Any newly admitted individual who has a psychiatric diagnosis or is receiving psychotropic medication. D. The psychiatrist must diagnose and document the psychiatric disorder in accordance with the current Diagnostic and Statistical Manual (DSM) and/or the current clinical modification of the International Statistical Classification of Diseases and Related Health Problems. E. The psychiatrist s assessment and diagnosis must be consistent with current generally accepted professional standards of care as described in Exhibit B to this policy (Appendix B of the Settlement Agreement.) F. All individuals must receive an annual psychiatric update/addendum for the comprehensive psychiatric evaluation (CPE), completed annually from the date of the last CPE or last CPE addendum. IV. Treatment Management A. All individuals must receive an assessment, a diagnosis, and a case formulation consistent with current, generally accepted professional standards of care (see Exhibit B). B. Treatment plans must integrate pharmacological treatments with behavioral and other interventions. C. Prior to implementing a proposed discipline-specific non-pharmalogical plan or plans, the IDT, including a psychiatrist, must determine that the plan or plans: 1. Includes the least intrusive and most positive intervention; 2. Addresses whether the individual will be best served primarily through behavioral, pharmacological, or other interventions, in combination or alone; and 3. Identifies non-pharmacological treatments, interventions, and supports that are being used to address the signs and symptoms of the disorder in order to minimize the need for psychotropic medication to the degree possible. D. The determination of the plan or plans addressed in C above, may occur in person or through a telephonic communication, including during the psychiatric clinic, and the determination of these items must be documented in writing. E. When medications are prescribed to treat both seizures and a mental health disorder, the neurologist and psychiatrist must coordinate the use of medications through the IDT process. Page 4 of 10
5 V. Psychotropic Medications A. Prior to prescribing psychotropic medications known to cause movement disorders, a trained and competent staff member must screen the individual for abnormal involuntary movements using the MOSES and DISCUS as determined necessary by the psychiatrist and document the result of the examination. B. The psychiatrist must indicate psychotropic medications used to treat specific target behaviors with an appropriate psychiatric diagnosis or a specific behavioralpharmacological hypothesis. C. Before the non-emergency administration of psychotropic medication, the IDT, including the psychiatrist, primary care physician, and nurse must determine whether the harmful effects of the individual's mental illness outweigh the possible harmful effects of psychotropic medication and whether reasonable alternative treatment strategies are likely to be less effective or potentially more dangerous than the medications. This determination may occur in person or through a telephonic communication, including during the psychiatric clinic, and the determination must be documented in writing. D. The psychiatrist must solicit input from and discuss with the IDT any proposed alternative treatment, incorporating behavioral and other interventions to minimize the need for psychotropic medication to the degree possible. E. For every individual receiving psychotropic medication, the IDT, including the psychiatrist, must: 1. Ensure that the treatment plan for the psychotropic medication identifies a clinically justifiable diagnosis or a specific behavioral-pharmacological hypothesis; 2. Determine the expected timeline for the therapeutic effects of the medication to occur; 3. Determine the objective psychiatric symptoms or behavioral characteristics that will be monitored to assess the treatment s efficacy; 4. Determine by whom, when, and how this monitoring will occur; and 5. Provide ongoing monitoring of the psychiatric treatment identified in the treatment plan, as often as necessary, based on the individual s current status and/or changing needs, but no less often than quarterly. F. The psychiatrist, in conjunction with the pharmacist and appropriate staff, must conduct quarterly reviews of the risk versus benefit of continued psychotropic medication therapy as well as the appropriateness of drug selection, effectiveness, Page 5 of 10
6 dosage, and presence or absence of side effects. The psychiatrist documents the review in the active record. The pharmacist s input must include the written quarterly Drug Regimen Review, but may also include participation in the discussion. G. The prescribing professional must document quarterly the rationale for initiating, continuing or discontinuing psychotropic medication in the active record. H. Each month, the psychiatrist and designated staff must review and monitor individuals who are prescribed two or more psychotropic medications from the same class, or three or more psychotropic medications, regardless of the class. The pharmacist must develop a plan to eliminate polypharmacy that are not clinically justified. I. The prescribing professional must monitor required parameters using the state monitoring guidelines. The guidelines can be found online at: J. Psychotropic Medications Ordered for Emergencies 1. The prescribing professional may order the immediate administration of psychotropic medication for a psychiatric emergency. State centers must have procedures for emergency use of psychotropic medications. The procedures for emergency use must address: a. Indications; b. Appropriate medication classes and dosing, including maximum dose in 24 hours; c. Assessment of effectiveness; d. Staff monitoring of individual for adverse reactions; e. Individual education as appropriate; f. Review with consideration of changing the current plan of care if a pattern of use of psychiatric emergency orders emerges; and g. Documentation of time frames and standards that address the incident, the use of medications, and the outcome. K. The psychiatrist must assess and document a psychiatric emergency in the psychiatry notes as soon as feasible after the emergency. VI. Monitoring for Medication Side Effects Page 6 of 10
7 A. All staff providing care for individuals who are receiving psychotropic medications must be aware of the side effects and must regularly monitor those individuals for the side effects. B. The nursing staff must complete the Monitoring of Side Effects Scale (MOSES) every six months and the Dyskinesia Identification System Condensed User Scale (DISCUS) every three months for all individuals receiving psychoactive medications. (See Exhibit A, Psychotropic Medication List for MOSES/DISCUS requirements.) In addition, nursing staff must complete: 1. a MOSES and DISCUS when a new psychotropic medication is initiated (only for specific medications as listed on the Psychotropic Medication List, unless specified by prescriber); 2. a DISCUS once a month for three months after an antipsychotic or metoclopramide is discontinued and every three months until symptoms are resolved; and 3. a MOSES and DISCUS within 30 days of a psychoactive medication dose change, as clinically determined necessary by the psychiatrist. C. The psychiatrist must review the results of these scales to monitor the side effects of psychotropic medications. VII. Dyskinesia A. A psychiatrist, neurologist, or primary care provider must verify the diagnosis of movement disorder, including tardive dyskinesia. B. The professional who diagnoses the dyskinesia must document the duration and severity of dyskinesia in the individual s individual progress notes (IPN). C. The prescribing professional must document the diagnosis in the CPE/updated CPE and include relevant information and justification for continued antipsychotic use. D. State centers must provide the individual and LAR with relevant education about the diagnosis and its implications for psychotropic medication use. E. The prescribing professional must assess the risks and benefits of continued psychotropic medication use and communicate these to the individual and LAR. F. The prescribing professional, if not a psychiatrist or neurologist, must obtain and document consultation from a psychiatrist or neurologist if continued use of psychotropic medication is considered after the diagnosis of tardive dyskinesia. VIII. Documentation Page 7 of 10
8 A. All clinical documentation must be accurate and legible and must include date, time, and signature. B. Psychiatric assessments must be typed or transcribed. C. Progress notes may be handwritten, typed, or transcribed. If handwritten, notes must be legible. Progress notes must use the SOAP (subjective, objective, assessment, and plan) format. D. Documentation of Acute Psychiatric Problems 1. When documenting the assessment of an individual with an acute psychiatric problem, include: a. A comprehensive history of the problem, including relevant past medical history and, in an emergent situation, a complete review of the relevant history; b. The source of the information (e.g., direct support professional, licensed vocational nurse, registered nurse, qualified developmental disability professional, psychologist, past medical history); c. All pertinent physical examination findings; d. Results of diagnostic tests; e. A differential diagnosis based on current DSM and, if needed, DM-ID nomenclature; and f. A plan for treatment, as well as further evaluation, treatments, and monitoring. 2. Document follow-up assessments until the problem is resolved or has stabilized. 3. Specific medical orders include instructions for the monitoring that the psychiatrist expects from the nursing, psychology, direct support professionals, and/or any other staff for ongoing assessment of the acute problem. E. Orders 1. List indication(s) for each medication on all orders. 2. Document the rationale for medical orders representing a significant change in therapy in a progress note. 3. Orders may be typed, transcribed, or handwritten. Page 8 of 10
9 4. Orders only include abbreviations approved by the state center. 5. Ensure that results of laboratory tests are reviewed and critical lab values are addressed and documented. IX. Quality Assurance A. State centers must monitor and address quality of psychotropic medication-related services. The review must include the following per the psychiatric monitoring tool: 1. Clinically justifiable evaluation/diagnosis; 2. Use of psychotropic medication; 3. Pre-treatment sedation; 4. Procedure for psychiatric assessment; 5. Reiss Screen, if positive for maladaptive behavior; 6. Non-pharmacological treatments, interventions, or supports to address signs and symptoms in order to minimize the need for psychotropic medication to the degree possible; 7. Risk versus benefit; 8. Psychotropic polypharmacy; 9. MOSES and DISCUS; 10. Treatment plans for psychotropic medications; 11. Informed consent; and 12. Collaboration with neurology. B. State centers must establish a system to review and monitor individuals who are prescribed two or more psychotropic medications from the same class, or three or more psychotropic medications, regardless of the class. The monitoring system must track and trend prescribing information by individual, by prescriber, and by medication. C. State centers must establish a tracking system for using the MOSES or DISCUS to monitor, detect, report, and respond to side effects of psychotropic medications at least quarterly or as needed. Page 9 of 10
10 D. State centers may develop tracking systems as needed for other areas. X. Data Collection A. Each state center tracks, trends, and analyzes the number of: 1. Individuals on psychotropic medications; 2. Individuals who are prescribed two or more psychotropic medications from the same class, or three or more psychotropic medications, regardless of the class; 3. Completed comprehensive psychiatric assessments; 4. Individuals for whom a MOSES or DISCUS was completed; and 5. Individuals who have tardive dyskinesia. B. The state center psychiatrist or designee submits data to the State Office data analyst at the end of each quarter of the fiscal year. Page 10 of 10
11 DRAFT Definitions (to be added to the Definitions Dictionary) Case formulation: A process of review and integration of the information obtained from clinical assessments to identify factors that are hypothesized to influence an individual s condition, functional abilities, and quality of life. The process involves the participation of various clinical disciplines, including psychology, applied behavior analysis, and psychiatry. The result of case formulation should aid the IDT in making decisions regarding the support and services needed for individuals with a behavioral disturbance or psychopathology. (See Sections I.E. and IV.A. and Exhibit B of this policy for more information). Contractor: A person who contracts with a facility to provide services to an individual, including an independent school district that provides educational services at the facility. (40 TAC 3.101) DM-ID: Diagnostic Manual-Intellectual Disability: A Clinical Guide for Diagnosis of Mental Disorders in Persons with Intellectual Disability, a joint publication of the National Association for the Dually Diagnosed and the American Psychiatric Association which provides information relevant to making accurate diagnosis in persons with intellectual disability and addresses the limitations in applying DSM-IV-TR criteria to persons with intellectual disability. DSM: The current edition of The Diagnostic and Statistical Manual of Mental Disorders published by the American Psychiatric Press. (40 TAC 5.3(3)) Emergency: A situation which, in the opinion of the treating physician or other appropriate professional, the immediate use of medication is necessary for acute treatment or essential to interrupt imminent danger to the individual served or others. (40 TAC 8.203(4)) Individual support plan (ISP): An integrated, coherent, person-directed plan that reflects an individual's preferences, strengths, needs, and personal vision, as well as the protections, supports, and services the individual will receive to accomplish identified goals and objectives. (40 TAC 3.101) Interdisciplinary team (IDT): An interdisciplinary team, with the active participation of the individual and legally authorized representative (LAR), that is responsible for assessing the individual's treatment, training, and habilitation needs and making recommendations for services based on the personal goals and preferences of the individual using a person-directed planning process, including recommendations on whether the individual is best served in a facility or community setting. (40 TAC 3.101) Legally authorized representative (LAR): A person authorized by law to act on behalf of an individual, including a parent, guardian, or managing conservator of a minor individual, or a guardian of an adult individual. (40 TAC 3.101) DRAFT Definitions for 007 Psychiatry Policy 2013
12 Polypharmacy: The prescription of two or more psychotropic medications from the same general class (e.g., two antipsychotics) to the same individual, and the prescription of three or more psychotropic medications, regardless of class, to the same individual. (Settlement Agreement, Part II, Section J11) Positive behavior support plan (PBSP): A comprehensive, individualized plan that contains intervention strategies designed to modify the environment, teach or increase adaptive skills, and reduce or prevent the occurrence of target behaviors through interventions that build on an individual's strengths and preferences, without using aversive or punishment contingencies. The PBSP is a component of the Individual Support Plan (ISP). (40 TAC and Settlement Agreement, Part II, Section A.3.) Prescribing professional: A physician or other health care professional who, as authorized by statute, may prescribe under the supervision of a physician. (40 TAC 5.3(10)) Primary care provider (PCP): A physician, advanced practice registered nurse, or physician assistant who provides primary care to a defined population of patients. The PCP is involved in health promotion, disease prevention, health maintenance, and diagnosis and treatment of acute and chronic illnesses. (40 TAC 3.101) Psychiatric Emergency: A situation in which, in the opinion of the physician, it is immediately necessary to administer medication to an individual to ameliorate the signs and symptoms of mental illness and to prevent: a. Imminent probable death or substantial bodily harm to the individual because the individual: i. Overtly or continually is threatening or attempting to commit suicide or serious bodily harm; or ii. Is behaving in a manner that indicates that the individual is unable to satisfy the individual s need for nourishment, essential medical care, or self-protection; or b. Imminent physical or emotional harm to others, because of threats, attempts, or other acts the individual makes or commits. (40 TAC 5.3(12)) Psychiatrist: A physician who is certified by the American Board of Psychiatry and Neurology, or who is board-eligible (has completed a residency training program in psychiatry approved by the Residency Review Committee of the American Council on Graduate Medical Education). Psychotropic medication: A medication prescribed for the treatment of symptoms of psychosis or other severe mental or emotional disorders and that is used to exercise an effect on the central nervous system to influence and modify behavior, cognition, or DRAFT Definitions for 007 Psychiatry Policy 2013
13 affective state. Psychotropic medications include antipsychotics and neuroleptics; antidepressants; agents for the control of mania or depression; antianxiety agents; sedatives, hypnotics or other sleep-promoting drugs; psychomotor stimulants, and medications used for treatment of dementia. DRAFT Definitions for 007 Psychiatry Policy 2013
14 Executive Formulary Committee January 2012 Classes of Medications Frequently Used for Psychiatric Indications Consent is required for any medication that is used in the treatment of a psychiatric diagnosis or symptom, whether or not the medication is included in this list. Refer to physician order for determination of indication for use. The classification of psychotropic medication is fairly standard but medications can be used for treatment of illnesses that would be considered listed under a different classification. For example, some medications listed under antipsychotics may be used as a mood stabilizer. MOSES and/or DISCUS requirement in red. Antidepressants (MOSES) amitriptyline (Elavil) amoxapine (Asendin) bupropion (Wellbutrin, Wellbutrin SR) bupropion (Wellbutrin XL) citalopram (Celexa) desipramine (Norpramin) desvenlafaxine (Pristiq) nonformulary doxepin (Sinequan) duloxetine (Cymbalta) escitalopram (Lexapro) fluoxetine (Prozac) imipramine (Tofranil) maprotiline (Ludiomil) mirtazapine (Remeron, Remeron SolTab) nefazodone (Serzone) nonformulary nortriptyline (Pamelor, Aventyl) paroxetine (Paxil, Paxil CR) protriptyline (Vivactil) sertraline (Zoloft) trazodone (Desyrel) trimipramine (Surmontil) venlafaxine (Effexor, Effexor XR) Antipsychotics (MOSES and DISCUS) aripiprazole (Abilify) asenapine (Saphris) chlorpromazine (Thorazine) clozapine (Clozaril, Fazaclo) Reserve droperidol (Inapsine) nonformulary fluphenazine (Prolixin) fluphenazine decanoate (Prolixin D) haloperidol (Haldol) haloperidol decanoate (Haldol D) iloperidone (Fanapt) Reserve loxapine (Loxitane) lurasidone (Latuda) olanzapine (Zyprexa, Zyprexa Zydis) olanzapine pamoate (Zyprexa Relprevv) Reserve paliperidone (Invega) paliperidone palmitate (Invega Sustenna) perphenazine (Trilafon) pimozide (Orap) nonformulary quetiapine (Seroquel) quetiapine (Seroquel XR) nonformulary risperidone (Risperdal, Risperdal M-Tab) risperidone (Risperdal Consta) thioridazine (Mellaril) thiothixene (Navane) Anxiolytics/Sedatives/Hypnotics (MOSES) alprazolam (Xanax, Xanax XR) buspirone (BuSpar) chloral hydrate (Noctec) chlordiazepoxide (Librium) clonazepam (Klonopin) clorazepate (Tranxene) diazepam (Valium) diphenhydramine (Benadryl) eszopiclone (Lunesta) nonformulary flurazepam (Dalmane) nonformulary hydroxyzine (Atarax, Vistaril) lorazepam (Ativan) oxazepam (Serax) pentobarbital (Nembutal) nonformulary ramelteon (Rozerem) nonformulary temazepam (Restoril) triazolam (Halcion) zaleplon (Sonata) zolpidem (Ambien) Mood Stabilizers (MOSES) carbamazepine (Tegretol, Tegretol XR, Carbatrol, Equetro) divalproex sodium (Depakote, Depakote ER) lithium (Eskalith, Eskalith CR, Lithobid) valproic acid (Depakene) oxcarbazepine (Trileptal) lamotrigine (Lamictal) Stimulants (MOSES) amphetamine/dextroamphetamine mixture (Adderall, Adderall XR) dexmethylphenidate (Focalin) nonformulary dextroamphetamine (Dexedrine) lisdexamfetamine (Vyvanse) nonformulary methamphetamine (Desoxyn) nonformulary methylphenidate (Ritalin, Ritalin SR, Concerta, Metadate, Metadate CD) methylphenidate patch (Daytrana) nonformulary Chemical Dependency Adjuncts (MOSES) acamprosate (Campral) nonformulary disulfiram (Antabuse) naltrexone (ReVia, Vivitrol) topiramate (Topamax) Updated 2013 Page 1 of 2
15 trifluoperazine (Stelazine) ziprasidone (Geodon) Monoamine Oxidase Inhibitors (MOSES) isocarboxazid (Marplan) phenelzine (Nardil) selegiline (Emsam) nonformulary tranylcypromine (Parnate) Miscellaneous Drugs (per provider) atomoxetine (Strattera) atenolol (Tenormin) clomipramine (Anafranil) clonidine (Catapres) clonidine ER (Kapvay) nonformulary fluvoxamine (Luvox) gabapentin (Neurontin) guanfacine (Tenex) guanfacine ER (Intuniv) nonformulary metoprolol (Lopressor) nadolol (Corgard) propranolol (Inderal) reserpine (Serpasil) nonformulary naltrexone (ReVia) olanzapine/fluoxetine (Symbyax) nonformulary pindolol (Visken) nonformulary Other Medications requiring MOSES and DISCUS) Metoclopramide (Reglan) Anticholinergics Updated 2013 Page 2 of 2
16 EXHIBIT B I. Identifying Information a. Name b. Age c. Gender d. Ethnicity e. Housing f. Marital status STATE CENTERS Psychiatric Evaluations/Assessments II. History of Present Illness a. Behavioral concerns: antecedents, frequency, intensity, duration b. Substance use c. Suicidal/homicidal ideation d. Current medications, pattern of use, efficacy e. Psychiatric symptoms f. Neuro-vegetative symptoms III. Past Psychiatric History a. Inpatient treatment b. Outpatient treatment c. Medication history d. Previous diagnosis e. Trauma history f. History of self-injury, suicide, aggression to others IV. Family History a. Psychiatric disorders b. Medical disorders, especially diabetes, cardiovascular disease, CVA, HTN c. Neurological syndromes V. Substance Use History a. Alcohol: first drink, DUI, blackouts, current pattern b. Drugs of abuse, including IVDU c. Tobacco d. Caffeine VI. Medical History a. Active conditions b. Past history c. Current medications d. Allergies e. Diet f. Exercise habits EXHIBIT B - Psychiatric Evaluations/Assessments ( /13) Page 1 of 3
17 VII. Developmental History a. Prenatal and birth history b. Early development c. Family relationships d. Educational history VIII. Social History a. Relationship history (marriage, partner, children) b. Work history c. Legal history d. Sexual history IX. Physical Examination a. Pertinent positives and negatives b. Neurological findings X. Labs a. Urine drug screen b. Pertinent positives and negatives XI. Mental Status Examination a. General observations i. Appearance (jewelry, scars, tattoos) ii. Behavior (eye contact/calm/agitated, psychomotor slowing/pressure/agitation) iii. Speech iv. Cooperativeness b. Thinking i. Thought process (logical, goal-directed, loose, tangential, circumstantial, overinclusive) ii. Thought content (preoccupations, delusions, suicidal ideation, homicidal ideation) iii. Perception (auditory, tactile, visual, olfactory, gustatory hallucinations) c. Emotion i. Affect ii. Mood d. Cognition i. Orientation ii. Attention and concentration iii. Memory iv. Insight v. Judgment XII. Diagnostic Assessment (five axes) a. Provide clinically justifiable diagnoses for each individual. All diagnoses that cannot be clinically justified for an individual are discontinued no later than the next review. b. The documented justification of diagnoses is in accord with the criteria contained in the most current DSM (as per DSM-IV-TR Checklist). EXHIBIT B - Psychiatric Evaluations/Assessments (02/13/13) Page 2 of 3
18 c. Differential diagnoses, deferred, or rule-out diagnoses, and a diagnoses as listed as NOS ( Not Otherwise Specified ) are timely addressed (i.e., within 60 days), through clinically appropriate assessments, and resolved in a clinically justifiable manner. d. If the determination is no diagnoses this is considered to be clinically justified and documented. XIII. Bio-Psycho-Social-Spiritual Formulation (Case Formulation) Case formulation consists of the following sequential tasks, undertaken to channel distinct disciplinary assessments into the creation of an integrated treatment plan: a. Review and integration of information from the disciplinary assessments; b. Identification of important factors, in a biological psychological social and spiritual hierarchy, that affect the individual's condition, functional abilities, and quality of life; c. Creation of clinically based predictions about the individual's needs; and d. Design of integrated treatment, habilitation, and enrichment interventions, through the interdisciplinary treatment process, to meet the individual's needs. e. Identification of concerns related to individual s preferences, strengths, and needs XIV. Treatment Recommendations a. Pharmacological intervention (includes psychoactive polypharmacy) b. Non-pharmacological intervention XV. Community Placement a. Assessment identifies supports and obstacles to placement b. Interdisciplinary Team members recommendation regarding appropriateness of community placement EXHIBIT B - Psychiatric Evaluations/Assessments (02/13/13) Page 3 of 3
PSYCHOSOMATIC INSTITUTE OF SAN ANTONIO New Patient Information
PSYCHOSOMATIC INSTITUTE OF SAN ANTONIO New Patient Information Name: Last: First: MI: Birth Date: Sex: M F Marital Status: Single Married Divorced Separated Widowed Partnered Other Preferred name: Emergency
More informationPSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS. Juanaelena Garcia, MD Psychiatry Director Institute for Family Health
PSYCHOPHARMACOLOGY AND WORKING WITH PSYCHIATRY PROVIDERS Juanaelena Garcia, MD Psychiatry Director Institute for Family Health Learning Objectives Learn basics about the various types of medications that
More informationEarly Morning Waking Excessively Orderly or Perfectionistic
COLLEGE OF MEDICINE Jacksonville 580 W 8 th St T-2 6 th Fl Ste 6005 6266 Dupont Station Ct Department of Psychiatry Jacksonville, FL 32209 Jacksonville, Fl 32217 Division of Adult Psychiatry Phone 904-383-1038
More informationPsychiatric Medications: Pearls and Pitfalls. The majority of medications used in patients with psychiatric diagnoses have more than one use.
Psychiatric Medications: Pearls and Pitfalls Rule #1 The majority of medications used in patients with psychiatric diagnoses have more than one use. Without access to the patient s medical record, to review
More informationArizona Department of Health Services/ Division of Behavioral Health Services Behavioral Health Drug List Effective 1/1/2014
Arizona Department of Health Services/ Division of Behavioral Health Services Behavioral Health Drug List Effective 1/1/2014 The Arizona Department of Health Services, Division of Behavioral Health Services,
More informationLamictal, lamotrigine Lithium, lithobid, eskalith Depakote, valproate Trileptal, oxcarbazepine Tegretol, equetro, carbamazepine Atypicals (aripiprazole, abilify, olanzapine, zyprexa, invega, risperdal,
More informationMedications Used in the Management of Disruptive Behavior Disorders
The following medication chart is provided as a brief guide to some of the medications used in the management of various behavior disorders, along with their potential benefits and possible side effects.
More informationPsychiatric Evaluation Intake Form
Psychiatric Evaluation Intake Form 1. Patient Contact Information Patient Name Preferred Name Last First MI Address_ Best contact phone number: Email address: Primary Care Physician Tel Fax Pharmacy Phone
More informationMedications A detailed booklet that describes mental disorders and the medications for treating them includes a comprehensive list of medications.
A detailed booklet that describes mental disorders and the medications for treating them includes a comprehensive list of medications. 2014 Contents Introduction: Mental Health Medications...1 What are
More informationHandout 2 List of medications used to treat mental illness
Navigating Boundaries: Setting Sail With A Mentally Ill Client Handout 2 List of medications used to treat mental illness Information synthesized from www.drugs.com. Additional Information: CR following
More informationMental Health Medications
Mental Health Medications National Institute of Mental Health U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Contents Mental Health Medications..............................................................1
More informationYOUR MEDICATIONS WHAT YOU SHOULD KNOW
YOUR MEDICATIONS WHAT YOU SHOULD KNOW A Handbook For People With Developmental Disabilities Developmental Disabilities Area Board 10 Developmental Disabilities Area Board 10 411 N. Central Avenue Suite
More informationPSYCHIATRY. Patient Name: Date: / / Date of Birth: / / Age: Pharmacy Name: Pharmacy Phone #:
Patient Name: Date: / / Date of Birth: / / Age: Pharmacy Name: Pharmacy Phone #: Primary Care Physician: Current Therapist/Counselor: How did you hear about us? Internet Insurance Other Providers (specialty):
More informationSECTION M BEHAVIORAL HEALTH SERVICES
Phoenix Health Plan s (PHP) goal for its members is to ensure that behavioral health services are readily available for Title XIX (Medicaid) and the Title XXI (KidsCare) members. Comprehensive behavioral
More informationAntipsychotics and the Nursing Home
Antipsychotics and the Nursing Home Lisa M. O Hara, PharmD, CGP Corporate Director of Clinical Services The State Operations Manual Part 1: F329 Unnecessary Drugs Medication Management Defined Helps promote
More informationSerenity Psychiatry, LLC Mimi Armellino, DO Of Coastal Counseling Associates. Patient History Form
Serenity Psychiatry, LLC Mimi Armellino, DO Of Coastal Counseling Associates Patient History Form Name Date Age DOB SSN Address City State ZIP Patient s Telephone (H) (W) (Cell) Email Job Title or School
More informationA BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES
INTRODUCTION A BRIEF OVERVIEW OF PSYCHOTROPIC MEDICATION USE FOR PERSONS WITH INTELLECTUAL DISABILITIES Individuals with intellectual disabilities are not uncommonly prescribed psychotropic medications.
More informationEMORY CLINIC, INC. Brain Health Center 12 Executive Park Dr. Atlanta, GA 30329 404-728-6302
New Patient Packet 03/10/2015 EMORY CLINIC, INC. Brain Health Center 12 Executive Park Dr. Atlanta, GA 30329 404-728-6302 Thank you for allowing us to assist in your care. We look forward to meeting you.
More information12629 LIBRIUM CHLORDIAZEPOXIDE HCL 12637 LIBRIUM CHLORDIAZEPOXIDE HCL 12645 LIBRIUM CHLORDIAZEPOXIDE HCL 13110 VALIUM DIAZEPAM 13277 VALIUM DIAZEPAM 24406 LITHANE LITHIUM CARBONATE 25836 SURMONTIL TRIMIPRAMINE
More informationState of Louisiana. Department of Health and Hospitals Bureau of Health Services Financing
Bobby Jindal GOVERNOR State of Louisiana Department of Health and Hospitals Bureau of Health Services Financing Kathy H. Kliebert SECRETARY The purpose of this memo is to advise you that effective September
More informationNew Treatments. For Bipolar Disorder. Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine
New Treatments For Bipolar Disorder Po W. Wang, MD Clinical Associate Professor Bipolar Disorders Clinic Stanford University School of Medicine Abbott Laboratories AstraZeneca Bristol-Myers Squibb Corcept
More informationMedication Side Effects:
Medication Side Effects: Staying Healthy While on Psychotropic Medications Megan Maroney PharmD, BCPP Clinical Assistant Professor Ernest Mario School of Pharmacy Rutgers the State University of New Jersey
More informationPSYCHIATRIC MEDICATION USE DURING PREGNANCY AND BREASTFEEDING
E-Resource May 2014 PSYCHIATRIC MEDICATION USE DURING PREGNANCY AND BREASTFEEDING Psychotropic medication use during pregnancy may have adverse effects, however, there is a growing body of evidence that
More informationOverview of Mental Health Medication Trends
America s State of Mind Report is a Medco Health Solutions, Inc. analysis examining trends in the utilization of mental health related medications among the insured population. The research reviewed prescription
More informationWhy is medication recommended as part of the treatment for mental illness?
Medications for Psychiatric Disorders Introduction This article discusses medications for psychiatric disorders. Information is provided about the effects of medications, including their advantages and
More informationPsychotropic Medication Reference Chart
Psychotropic Medication Reference Chart Appendix 4.14 This chart is not an all-inclusive list of medications. If you have a question regarding the classification of a medication you may consult websites
More informationOral Fluid Drug Testing March 23 rd, 2015
Oral Fluid Drug Testing March 23 rd, 2015 Drug Testing Options Breath Blood Meconium Vitreous Hair Sweat Urine Oral Drug Testing Options Oral Fluid and Blood and Breath Actual levels (immediate use, up
More informationPSYCHIATRIC MEDICATIONS AND HIV ANTIRETROVIRALS ADULT MANAGEMENT Winter 2013 ADRUGINTERACTIONGUIDEFORCLINICIANS
PSYCHIATRIC MEDICATIONS AND HIV ANTIRETROVIRALS ADULT MANAGEMENT Winter 2013 ADRUGINTERACTIONGUIDEFORCLINICIANS Psychiatric Medications and HIV Antiretrovirals: A Drug Interaction Guide for Clinicians
More informationUniversity of Florida & Shands Adult Psychiatry Outpatient Clinic Intake Form
University of Florida & Shands Adult Psychiatry Outpatient Clinic Intake Form Date Name Age Address Home phone Work phone Cell phone What issue(s) bring(s) you to the Psychiatry Clinic? What has been stressing
More informationUpdated MAR 26, 2013 Myelography Seizures:
Updated MAR 26, 2013 Myelography Medications to be evaluated prior to myelography. This list is to assist the radiologist, pharmacist, and radiology technologist in evaluating medication risk associated
More informationPOPULAR DEPRESSION MEDICATIONS
Popular Depression Medications A Helpful Guide to Antidepressant Drugs POPULAR DEPRESSION MEDICATIONS A Helpful Guide to Antidepressant Drugs Popular Depression Medications A Helpful Guide to Antidepressant
More informationPARTNERSHIP HEALTHPLAN OF CALIFORNIA MEDI-CAL PROVIDER MANUAL CLAIMS DEPARTMENT
PARTNERSHIP HEALTHPLAN OF CALIFORNIA MEDI-CAL PROVIDER MANUAL CLAIMS DEPARTMENT X.J. Mental Health Services 1. For claims with dates of service on or before January 1, 2014: Mental Health Services are
More informationObjectives. The use of Psychotropics in Children
Objectives The use of Psychotropics in Children Ashley E. Little, Pharm.D. Psychopharmacology Resident Nova Southeastern University College of Pharmacy Dade County Pharmacy Association To understand current
More informationPsychotropic Medication
Page 1 T I P S F O R P R A C T I C E Psychotropic Medication Psychotropic medications are symptomatic medications that affect attention, emotions, or behaviors. Communication between the physician, NDHHS
More informationRecognition and Treatment of Depression in Parkinson s Disease
Recognition and Treatment of Depression in Parkinson s Disease Web Ross VA Pacific Islands Health Care System What is depression? Depression is a serious medical condition that affects a person s feelings,
More informationWhat are the best treatments?
What are the best treatments? Description of Condition Depression is a common medical condition with a lifetime prevalence in the United States of 15% among adults. Symptoms include feelings of sadness,
More informationDepression. Medicines To Help You
Medicines To Help You Depression Use this guide to help you talk to your doctor, pharmacist, or nurse about your medicines for depression. The guide lists all of the FDA-approved products now available
More informationBIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS
BIPOLAR DISORDER A GUIDE FOR INDIVIDUALS AND FAMILIES FOR THE TREATMENT OF BIPOLAR DISORDER IN ADULTS A publication of the Massachusetts Department of Mental Health and the Massachusetts Division of Medical
More informationBipolar Disorder. Mania is the word that describes the activated phase of bipolar disorder. The symptoms of mania may include:
Bipolar Disorder What is bipolar disorder? Bipolar disorder, or manic depression, is a medical illness that causes extreme shifts in mood, energy, and functioning. These changes may be subtle or dramatic
More informationMedicines for Treating Depression. A Review of the Research for Adults
Medicines for Treating Depression A Review of the Research for Adults Is This Information Right for Me? Yes, if: A doctor or other health care professional has told you that you have depression. Your doctor
More informationClinical Practice Guideline: Depression in Primary Care, Adult 4 Taft Court Rockville, MD 20850 www.mamsi.com
Clinical Practice Guideline: Depression in 4 Taft Court Rockville, MD 20850 www.mamsi.com 40 05 17 035 3/03 Once a primary care patient presents with depressive symptoms, the primary care physician makes
More informationMOOD DISORDERS PART II BIPOLAR AFFECTIVE DISORDER (BAD) Todd Stull, M.D. James Sorrell, M.D.
MOOD DISORDERS PART II BIPOLAR AFFECTIVE DISORDER (BAD) Todd Stull, M.D. James Sorrell, M.D. BIPOLAR AFFECTIVE DISORDER (BAD) General Assessment is challenging Input important Change in level of functioning
More informationPsychotropic Medications
Psychotropic Medications Medicating children and adolescents for psychiatric problems or learning disabilities continues to be an area of controversy. There are currently two opposing poles in this discussion.
More informationNew Patient Information. Address: City: State: Zip: Ph#: Cell#:
Patient Information: Last Name: New Patient Information First Name: Address: City: State: Zip: Ph#: Cell#: S.S.N: Email: May we contact you by email? Yes No Date of Birth: May we send you information about
More informationI. The Positive Symptoms...Page 2. The Negative Symptoms...Page 2. Primary Psychiatric Conditions...Page 2
SUTTER PHYSICIANS ALLIANCE (SPA) 2800 L Street, 7 th Floor Sacramento, CA 95816 SPA PCP Treatment & Referral Guideline Assessment & Treatment of Psychosis Developed March 1, 2003 Revised September 21,
More informationConcurrent substance use and mental health disorders An information guide
Concurrent substance use and mental health disorders An information guide W.J. Wayne Skinner, MSW, RSW; Caroline P. O Grady, RN, MN, PhD Christina Bartha, MSW, CSW; Carol Parker, MSW, CSW i Concurrent
More informationMEDICATIONS USED FOR BEHAVIORAL & EMOTIONAL DISORDERS
MEDICATIONS USED FOR BEHAVIORAL & EMOTIONAL DISORDERS A GUIDE FOR PARENTS, FOSTER PARENTS, FAMILIES, YOUTH, CAREGIVERS, GUARDIANS, AND SOCIAL WORKERS Final May 10, 2010 Overview This booklet is a guide
More informationPOST-TRAUMATIC STRESS DISORDER PTSD Diagnostic Criteria PTSD Detection and Diagnosis PC-PTSD Screen PCL-C Screen PTSD Treatment Treatment Algorithm
E-Resource March, 2014 POST-TRAUMATIC STRESS DISORDER PTSD Diagnostic Criteria PTSD Detection and Diagnosis PC-PTSD Screen PCL-C Screen PTSD Treatment Treatment Algorithm Post-traumatic Stress Disorder
More informationMedication Management Improvement System
Medication Management Improvement System Protocol #3: Falls and Dizziness Related to the Use of Central Nervous System-Active Medications Problem: Goal: Use of medications that increase risk of falls and
More informationMedications for Huntington s Disease Vicki Wheelock, M.D.
Medications for Huntington s Disease Vicki Wheelock, M.D. Director, HDSA Center of Excellence at UC Davis June 4, 2013 Outline Introduction and disclaimers Medications for cognitive symptoms Medications
More informationPROBLEM: PSYCHOSIS GOALS APPROACHES. Name: MR #: 2009 pacific point consultants 04/09
PROBLEM: PSYCHOSIS GOALS APPROACHES Behavior (only one is required to be monitored, per Title XXII): Either: A. new admission: currently assessing for behaviors. 1. 2. Atypical psychosis Bipolar, mania
More informationMember Rights & Responsibilities
Member Rights & Responsibilities Member Rights and Responsibilities Blue KC has updated our Member Rights & Responsibilities to be consistent across all of our HMO and PPO products. Blue KC members have:
More informationObjectives. Depression and Anxiety: Latest in treatment recommendations. At the conclusion of this presentation the attendee will be able to:
Depression and Anxiety: Latest in treatment recommendations Margaret A. Fitzgerald, DNP, FNP-BC, NP-C, FAANP, CSP, FAAN, DCC President, Fitzgerald Health Education Associates, Inc., North Andover, MA Family
More informationMelissa D. Carter, JD Barton Child Law & Policy Center Brent Wilson, MD Child Welfare Collaborative
Melissa D. Carter, JD Barton Child Law & Policy Center Brent Wilson, MD Child Welfare Collaborative Scope of the Problem Legal and Policy Considerations Social Work and Medical Practices Advocacy Opportunities
More informationDrug Class Review Drugs for Fibromyalgia
Drug Class Review Drugs for Fibromyalgia Final Original Report April 2011 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of the is to summarize key
More informationStandardized Procedures and Protocols for Nurse Practitioners in Psychiatry August 2013
Standardized Procedures and Protocols for Nurse Practitioners in Psychiatry August 2013 Contents Statement of Approval I Introduction II General Policy III General Protocols Approval Review and Revision
More informationDrugs with Anticholinergic Activity
PL Detail-Document #271206 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER December 2011 Drugs with Anticholinergic
More informationDisclosure Statement. Nursing Facility Regulations and Psychotropic Medication Use. Learning Objectives (Cont) Learning Objectives
Nursing Facility Regulations and Psychotropic Medication Use Jeffrey C. Reist PharmD, BCPS College of Pharmacy The University of Iowa December 2010 Disclosure Statement I, Jeffrey Reist, PharmD, BCPS do
More informationA few general principles regarding medications are important to consider before initiating therapy in individuals diagnosed with a dementia
MEDICATIONS USED FOR THE MANAGEMENT OF DEMENTIA AND RELATED BEHAVIORIAL COMPLICATIONS* R.Ron Finley, B.S Pharm, R.Ph,CGP, Aimee Loucks, Pharm. D., Gil D. Rabinovici, M.D The following is intended to be
More informationAlgorithm for Initiating Antidepressant Therapy in Depression
Algorithm for Initiating Antidepressant Therapy in Depression Refer for psychotherapy if patient preference or add cognitive behavioural office skills to antidepressant medication Moderate to Severe depression
More informationADULT FEMALE NEW PATIENT INFORMATION FORM
The Fort Christian Psychiatric Center Shaw Wendi Fortuchang, M.D., P.C. ADULT FEMALE NEW PATIENT INFORMATION FORM How were you referred to our office? Patient s Full Name Age: Date of Birth: Gender: Email
More informationTREATING MAJOR DEPRESSIVE DISORDER
TREATING MAJOR DEPRESSIVE DISORDER A Quick Reference Guide Based on Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Second Edition, originally published in April 2000.
More informationDisclosures Christer Allgulander
How Patients With Generalized Anxiety Disorder (GAD) Are Treated in Specialized Care: A Pharmacoepidemiological Case Register Study in Sweden Christer Allgulander MD, Karolinska Institutet, Sweden Jan
More informationD. Clinical indicators for psychiatric evaluation are established by one or more of the following criteria. The consumer is:
MCCMH MCO Policy 2-015 Date: 4/21/11 V. Standards A. A psychiatric evaluation shall be done as an integral part of the assessment process. It serves as the guide to the identification of medical and psychiatric
More informationbipolar disorder? BASIC FACTS SYMPTOMS FAMILIES TREATMENTS
W H A T I S bipolar disorder? BASIC FACTS SYMPTOMS FAMILIES TREATMENTS MENTAL ILLNESS RESEARCH, EDUCATION & CLINICAL CENTERVA DESERT PACIFIC Mental Illness Research, Education and Clinical Center Va desert
More informationdepression & medication
depression & medication LAURA PINSKY, LCSW COLUMBIA UNIVERSITY, CPS Depression and Medication Laura Pinsky, LCSW Columbia University Counseling and Psychological Service What is depression? In the language
More informationINNOVATIONA IN MODEL PROGRAMS: Empowered for Life Home Treatment for Behavioral Health Conditions
INNOVATIONA IN MODEL PROGRAMS: Empowered for Life Home Treatment for Behavioral Health Conditions Mary Lynn Stewart, RN, BSN, MSN Amedisys Home Health Care Learning Objectives: Identify key components
More informationATYPICALS ANTIPSYCHOTIC MEDICATIONS
The atypical antipsychotics are a class of drugs that are used to treat a number of behavioral health disorders, including schizophrenia, other psychotic disorders, mood disorders, and behavioral agitation
More informationComorbid Conditions in Autism Spectrum Illness. David Ermer MD June 13, 2014
Comorbid Conditions in Autism Spectrum Illness David Ermer MD June 13, 2014 Overview Diagnosing comorbidities in autism spectrum illnesses Treatment issues specific to autism spectrum illnesses Treatment
More informationCommunity Center Readiness Guide Additional Resource #17 Protocol for Physician Assistants and Advanced Practice Nurses
Community Center Readiness Guide Additional Resource #17 Protocol for Physician Assistants and Advanced Practice Nurses PROTOCOL FOR PHYSICIAN ASSISTANTS AND ADVANCED PRACTICE NURSES 1. POLICY Advanced
More informationComorbid Problems in Children and Adults with ADHD: Current Medication Interventions
Comorbid Problems in Children and Adults with ADHD: Current Medication Interventions CANP State Conference March 22, 2013 Monterey, CA Susan R. Opas, PhD, CPNP, CPMHS Workshop Objectives Review defining
More informationLegal Aspects of Antipsychotic Drug Use
Legal Aspects of Antipsychotic Drug Use How the Law Requires Good Dementia Care Using a Least Medicating Approach Anthony Chicotel Staff Attorney California Advocates for Nursing Home Reform This is Reggie
More informationPSYCHOTROPIC MEDICATIONS FOR BEHAVIORAL & EMOTIONAL DISORDERS
PSYCHOTROPIC MEDICATIONS FOR BEHAVIORAL & EMOTIONAL DISORDERS A GUIDE FOR PARENTS AND FAMILY MEMBERS, RESOURCE FAMILIES, YOUTH AND SOCIAL WORKERS June 2013 Table of Contents Page 3 How this Guide Can Help
More informationDepression Flow Chart
Depression Flow Chart SCREEN FOR DEPRESSION ANNUALLY Assess for depression annually with the PHQ-9. Maintain a high index of suspicion in high risk older adults. Consider suicide risk and contributing
More informationDepression is a common biological brain disorder and occurs in 7-12% of all individuals over
Depression is a common biological brain disorder and occurs in 7-12% of all individuals over the age of 65. Specific groups have a much higher rate of depression including the seriously medically ill (20-40%),
More informationThe following is a sample of psychotropic drug warnings that drug regulatory agencies
Chronology of International Drug Regulatory Agency Warnings about Psychotropic Drugs The following is a sample of psychotropic drug warnings that drug regulatory agencies around the world have issued.
More informationFamily Guide. West S p ring s Hos p ital
Family Guide West S p ring s Hos p ital Dear Family Members, We are appreciative of the opportunity to take care of your loved one at this difficult time. Please know that our objective is to provide
More informationTREATMENT-RESISTANT DEPRESSION AND ANXIETY
University of Washington 2012 TREATMENT-RESISTANT DEPRESSION AND ANXIETY Catherine Howe, MD, PhD University of Washington School of Medicine Definition of treatment resistance Failure to remit after 2
More informationMajor Depression. What is major depression?
Major Depression What is major depression? Major depression is a serious medical illness affecting 9.9 million American adults, or approximately 5 percent of the adult population in a given year. Unlike
More informationGUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS
GUIDELINES GUIDELINES FOR USE OF PSYCHOTHERAPEUTIC MEDICATIONS IN OLDER ADULTS Preamble The American Society of Consultant Pharmacists has developed these guidelines for use of psychotherapeutic medications
More informationWhat is Bipolar Disorder?
What is Bipolar Disorder? We all get excited by new ideas, pursue our goals with passion, have times when we want to party with our friends and enjoy life to its fullest. There will also be times when
More informationWelcome to Who Wants to be an APNA Millionaire!
Welcome to Who Wants to be an APNA Millionaire! Drug-Drinks Interactions Drug-Drug Interactions Mary Gutierrez, PharmD, BCPP Clinical Professor of Pharmacy Practice (Psychiatry) Chapman University, School
More informationTREATMENT OF BIPOLAR DISORDERS: A Guide for Patients and Families
TREATMENT OF BIPOLAR DISORDERS: A Guide for Patients and Families Sources: David A. Kahn, M.D., Ruth Ross, M.A., David J. Printz, M.D., and Gary S. Sachs, M.D., DSMIV, DBSA Bipolar disorder (also known
More informationDEMENTIA EDUCATION & TRAINING PROGRAM
The pharmacological management of aggression in the nursing home requires careful assessment and methodical treatment to assure maximum safety for patients, nursing home residents and staff. Aggressive
More informationASSISTED LIVING FACILITY PRIVATE PAY ASSESSMENT MANUAL
ASSISTED LIVING FACILITY PRIVATE PAY ASSESSMENT MANUAL Commonwealth of Virginia Department of Social Services Division of Family Services, Adult Services Program TABLE OF CONTENTS 1. PURPOSE OF THIS MANUAL...1
More informationGeneric and Brand Drug Names Purpose Usual Dose and Frequency Potential Side Effects Emergency Conditions Cautions Addiction Treatment Medications
Generic and Brand Drug Names Purpose Usual Dose and Frequency Potential Side Effects Emergency Conditions Cautions Addiction Treatment Medications Published in 2000 by the Mid-America Addiction Technology
More informationA Guide to Tourette Syndrome Medications by John T. Walkup M.D.
llllllllllllllll A TSA MEDICAL PUBLICATION A Guide to Tourette Syndrome Medications by John T. Walkup M.D. This publication is intended to provide information about Tourette Syndrome, its management and
More informationThis resource guide is provided by: NAMI Michigan
This resource guide is provided by: NAMI Michigan For more information, please contact us: 921 N. Washington Ave. Lansing, MI 48906 517.485.4049 800.331.4264 info@namimi.org www.namimi.org www.facebook.com/namiofmi
More informationDual Diagnosis in Treatment
Dual Diagnosis in Treatment Presented by: Dr. John E. Simon Psychiatrist, Vinland Center 1 John E. Simon, M.D. President, Creative Psychopharmacology Board Certified in Psychiatry Added Qualifications
More informationStimulants and Nonstimulants for ADHD
Stimulants and Nonstimulants for ADHD Stimulants Adderall and Adderall XR (amphetamine mixtures) Concerta (methylphenidate, extended release) Daytrana (methylphenidate topical patch) Dexedrine and Dexedrine
More informationMEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS. Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D.
MEDICATIONS AND TOURETTE S DISORDER: COMBINED PHARMACOTHERAPY AND DRUG INTERACTIONS Barbara Coffey, M.D., Cheston Berlin, M.D., Alan Naarden, M.D. Introduction Tourette Syndrome (TS) or Tourette s Disorder
More informationANTIDEPRESSANT MEDICINES. A GUIDE for ADULTS With DEPRESSION
ANTIDEPRESSANT MEDICINES A GUIDE for ADULTS With DEPRESSION August 2007 FAST FACTS ON ANTIDEPRESSANTS The antidepressants in this guide work for treating depression. Most people can find one that makes
More informationCountyCare Appropriate Uses and Safety Edits
CountyCare Appropriate Uses and Safety Edits The health and safety of our members are top priorities for CountyCare. One of the ways we address patient safety is through point-of-sale (POS) edits at the
More informationINNOVATIVE RESOURCE GROUP d/b/a APS HEALTHCARE, INC.
INNOVATIVE RESOURCE GROUP d/b/a APS HEALTHCARE, INC. APS CareConnection INSTRUCTIONS AND DEFINITIONS BY TIER: For completing the APS CareConnection for Behavioral Health Services offered by Private Practitioners
More informationPsychotic Disorder. Psychosis. Psychoses may be caused by: Examples of Hallucinations and Delusions 12/12/2012
Psychosis Psychotic Disorder Dr Lim Boon Leng Psychiatrist and Medical Director Dr BL Lim Centre For Psychological Wellness Tel: 64796456 Email: info@psywellness.com.sg Web: www.psywellness.com.sg A condition
More information[Provider or Facility Name]
[Provider or Facility Name] SECTION: [Facility Name] Residential Treatment Facility (RTF) SUBJECT: Psychiatric Security Review Board (PSRB) In compliance with OAR 309-032-0450 Purpose and Statutory Authority
More informationA Manic Episode is defined by a distinct period during which there is an abnormally and persistently elevated, expansive, or irritable mood.
Bipolar disorder Bipolar (manic-depressive illness) is a recurrent mode disorder. The patient may feel stable at baseline level but experience recurrent shifts to an emotional high (mania or hypomania)
More informationPreferred Practice Guidelines Bipolar Disorder in Children and Adolescents
These Guidelines are based in part on the following: American Academy of Child and Adolescent Psychiatry s Practice Parameter for the Assessment and Treatment of Children and Adolescents With Bipolar Disorder,
More informationAppendix B NMMCP Covered Services and Exceptions
Acute Inpatient Hospitalization MH - Adult Definition An Acute Inpatient program is designed to provide medically necessary, intensive assessment, psychiatric treatment and support to individuals with
More information